Pharmaceutical company Galderma has announced that the US Food and Drug Administration (FDA) has approved Restylane Lyft for the augmentation for the chin region.
The company shares that the combination of Restylane Lyft with lidocaine can improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion. This approval is based on results from 175 participants who were involved in a 12-month clinical study in the US conducted by Galderma. The study revealed a high proportion of patients agreed that Restylane Lyft delivered natural-looking chin projection, improved the appearance of the lower face and provided a smooth transition from chin to jawline, with satisfaction rates up to 86.3%.
Vice president of medical affairs at Galderma US, Bill Andriopoulos, commented, “This approval reinforces our commitment to advancing our injectable aesthetics portfolio – the broadest on the market – to meet the diverse needs of patients. By expanding how innovations like Restylane Lyft can be used, we aim to empower aesthetic practitioners to achieve their patients’ unique aesthetic goals with enhanced flexibility and precision.”
Atlanta biomedical clinical research and Georgia dermatology partners, cosmetic dermatologist, Dr Alia Brown added, “The FDA approval of Restylane Lyft for chin augmentation is a significant step forward for practitioners. The chin is essential for facial balance, and having a product that offers precision and flexibility means we can better tailor treatments to each patient’s unique goals. What makes this approval even more compelling is the strong clinical data behind it, showing high patient satisfaction and long-lasting results. It gives us confidence to deliver natural, harmonious outcomes that truly enhance overall facial aesthetics.”